Therapeutic Asset Ratings
394 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
mk-5684
Metastatic Neoplasm
Merck Sharp & Dohme LLC
P1/2
CC
(45)
Patritumab Deruxtecan
Cancer
Merck Sharp & Dohme LLC
P1/2
CC
(45)
Zilovertamab Vedotin
Ewing Sarcoma
Merck Sharp & Dohme LLC
P1/2
CC
(45)
Zilovertamab Vedotin
Neuroblastoma
Merck Sharp & Dohme LLC
P1/2
CC
(45)
Cyclophosphamide
Advanced/Metastatic Solid Tumors
Merck Sharp & Dohme LLC
P1
CC
(44)
Elpipodect
Bipolar I Disorder
Merck Sharp & Dohme LLC
P1
CC
(44)
Epirubicin
Advanced/Metastatic Solid Tumors
Merck Sharp & Dohme LLC
P1
CC
(44)
mk-4464
Advanced/Metastatic Solid Tumors
Merck Sharp & Dohme LLC
P1
CC
(44)
mk-4700
Cancer
Merck Sharp & Dohme LLC
P1
CC
(44)
MK8189
Schizophrenia
Merck Sharp & Dohme LLC
P1
CC
(44)
Cyclophosphamide
Programmed Cell Death 1 Ligand 1(PDL1, PD-L1)
Merck Sharp & Dohme LLC
P1
CC
(43)
Cyclophosphamide
Programmed Cell Death 1 Ligand 2 (PDL2, PD-L2)
Merck Sharp & Dohme LLC
P1
CC
(43)
Cyclophosphamide
Programmed Cell Death-1 (PD1, PD-1)
Merck Sharp & Dohme LLC
P1
CC
(43)
Epirubicin
Programmed Cell Death 1 Ligand 1(PDL1, PD-L1)
Merck Sharp & Dohme LLC
P1
CC
(43)
Epirubicin
Programmed Cell Death 1 Ligand 2 (PDL2, PD-L2)
Merck Sharp & Dohme LLC
P1
CC
(43)
Epirubicin
Programmed Cell Death-1 (PD1, PD-1)
Merck Sharp & Dohme LLC
P1
CC
(43)
GEH200520
Metastatic Neoplasm
Merck Sharp & Dohme LLC
P1
CC
(43)
mk-0482
Acute Myeloid Leukemia
Merck Sharp & Dohme LLC
P1
CC
(43)
mk-0482
Chronic Myelomonocytic Leukemia
Merck Sharp & Dohme LLC
P1
CC
(43)
mk-8294
Metastatic Neoplasm
Merck Sharp & Dohme LLC
P1
CC
(43)
Pembrolizumab
Programmed Cell Death 1 Ligand 1(PDL1, PD-L1)
Merck Sharp & Dohme LLC
P1
CC
(43)
Pembrolizumab
Programmed Cell Death 1 Ligand 2 (PDL2, PD-L2)
Merck Sharp & Dohme LLC
P1
CC
(43)
Pembrolizumab
Autoimmune Pulmonary Disease Due To PD-1 Deficiency
Merck Sharp & Dohme LLC
P1
CC
(43)
Sacituzumab Tirumotecan
Programmed Cell Death 1 Ligand 2 (PDL2, PD-L2)
Merck Sharp & Dohme LLC
P1
CC
(43)
Sacituzumab Tirumotecan
Autoimmune Pulmonary Disease Due To PD-1 Deficiency
Merck Sharp & Dohme LLC
P1
CC
(43)
Showing 326 to 350 of 394 assets
Previous
Page 14 of 16
Next